Global Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiology Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Chemotherapy Induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast-2030" report has been added to ResearchAndMarkets.com's offering.

This 'Chemotherapy Induced Peripheral Neuropathy (CIPN) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the CIPN, historical and forecasted epidemiology as well as the CIPN trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of CIPN, Severity Specific Incident Population of CIPN, Incident Population of CIPN by Chemotherapeutic Agents, and Incident Population of CIPN by Cancer Type scenario of CIPN in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Detailed Epidemiology Segmentation

• The United States showed the highest incident population of CIPN. As per the publisher's estimates, the US accounts for approximately 41.11% of total cases, for CIPN, in the 7MM countries. In 2017, the incident population of CIPN in the US was found to be 598,908.
• In 2017, incident cases of mild, moderate and severe CIPN in the US were 173,683, 305,443, and 119,782 respectively. Assessments as per the publisher's analysts show that the overall incidence of moderate CIPN was maximum, followed by mild and severe, and is subjected to increase rapidly in the coming years.
• In 2017, the incident population of CIPN in the US by cancer type accounted for 82,082 for Breast Cancer, 60,620 for colorectal cancer. CIPN in Lung Cancer patients were estimated to be 48,724 in 2017
• Among the European countries, Germany had the highest incident population of CIPN with 165,095 cases, followed by the United Kingdom which had the incident population of 120,624 in 2017. On the other hand, Spain had the lowest incident population of 73,071 in 2017.
• As per the publisher's estimates, Japan accounts for approximately 18.11% of the total incident cases in the 7MM. In 2017, the incident population of CIPN in Japan was found to be 263,842.

Scope of the Report

• The report covers the descriptive overview of CIPN, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden of CIPN.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of CIPN, Severity Specific Incident Population of CIPN, Incident Population of CIPN by Chemotherapeutic Agents, and Incident Population of CIPN by Cancer Type.

Report Highlights

• 11-Year Forecast of CIPN
• 7MM Coverage
• Total Incident Cases of CIPN
• Severity Specific Incident Population of CIPN
• Incident Population of CIPN by Chemotherapeutic Agents
• Incident Population of CIPN by Cancer Type

Key Questions Answered

• What are the disease risk and burden of CIPN?
• What is the historical CIPN patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of CIPN at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CIPN?
• Out of the above-mentioned countries, which country would have the highest incident population of CIPN during the forecast period (2020-2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

For more information about this report visit https://www.researchandmarkets.com/r/qj6gyq